Literature DB >> 16305368

The role of ABC transporters in drug resistance, metabolism and toxicity.

Hristos Glavinas1, Péter Krajcsi, Judit Cserepes, Balázs Sarkadi.   

Abstract

ATP Binding Cassette (ABC) transporters form a special family of membrane proteins, characterized by homologous ATP-binding, and large, multispanning transmembrane domains. Several members of this family are primary active transporters, which significantly modulate the absorption, metabolism, cellular effectivity and toxicity of pharmacological agents. This review provides a general overview of the human ABC transporters, their expression, localization and basic mechanism of action. Then we shortly deal with the human ABC transporters as targets of therapeutic interventions in medicine, including cancer drug resistance, lipid and other metabolic disorders, and even gene therapy applications. We place a special emphasis on the three major groups of ABC transporters involved in cancer multidrug resistance (MDR). These are the classical P-glycoprotein (MDR1, ABCB1), the multidrug resistance associated proteins (MRPs, in the ABCC subfamily), and the ABCG2 protein, an ABC half-transporter. All these proteins catalyze an ATP-dependent active transport of chemically unrelated compounds, including anticancer drugs. MDR1 (P-glycoprotein) and ABCG2 preferentially extrude large hydrophobic, positively charged molecules, while the members of the MRP family can extrude both hydrophobic uncharged molecules and water-soluble anionic compounds. Based on the physiological expression and role of these transporters, we provide examples for their role in Absorption-Distribution-Metabolism-Excretion (ADME) and toxicology, and describe several basic assays which can be applied for screening drug interactions with ABC transporters in the course of drug research and development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16305368     DOI: 10.2174/1567201043480036

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  157 in total

1.  Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo.

Authors:  Ke-Jun Liu; Jie-Hua He; Xiao-Dong Su; Hong-May Sim; Jing-Dun Xie; Xing-Gui Chen; Fang Wang; Yong-Ju Liang; Satyakam Singh; Kamlesh Sodani; Tanaji T Talele; Suresh V Ambudkar; Zhe-Sheng Chen; Hai-Ying Wu; Li-Wu Fu
Journal:  Int J Cancer       Date:  2012-06-13       Impact factor: 7.396

Review 2.  Coexistence of passive and carrier-mediated processes in drug transport.

Authors:  Kiyohiko Sugano; Manfred Kansy; Per Artursson; Alex Avdeef; Stefanie Bendels; Li Di; Gerhard F Ecker; Bernard Faller; Holger Fischer; Grégori Gerebtzoff; Hans Lennernaes; Frank Senner
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

3.  Inhibition of blood-brain barrier efflux transporters promotes seizure in pregnant rats: Role of circulating factors.

Authors:  Abbie C Johnson; Erica S Hammer; Sophie Sakkaki; Sarah M Tremble; Gregory L Holmes; Marilyn J Cipolla
Journal:  Brain Behav Immun       Date:  2017-07-21       Impact factor: 7.217

4.  STAT3 contributes to NK cell recognition by modulating expression of NKG2D ligands in adriamycin-resistant K562/AO2 cells.

Authors:  Xiaohui Cai; Xuzhang Lu; Zhuxia Jia; Xiuwen Zhang; Wenmin Han; Xiao Rong; Lingdi Ma; Min Zhou; Baoan Chen
Journal:  Int J Hematol       Date:  2015-09-19       Impact factor: 2.490

5.  MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer.

Authors:  Sha Xiao; Ming Zhang; Chang Liu; Deling Wang
Journal:  Mol Genet Genomics       Date:  2018-05-11       Impact factor: 3.291

Review 6.  Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking.

Authors:  Xue Xue; Matthew D Hall; Qiang Zhang; Paul C Wang; Michael M Gottesman; Xing-Jie Liang
Journal:  ACS Nano       Date:  2013-12-10       Impact factor: 15.881

Review 7.  Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.

Authors:  Ahmad R Safa; Travis W Day; Ching-Huang Wu
Journal:  Curr Cancer Drug Targets       Date:  2008-02       Impact factor: 3.428

8.  Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.

Authors:  Chun-ling Dai; Amit K Tiwari; Chung-Pu Wu; Xiao-Dong Su; Si-Rong Wang; Dong-geng Liu; Charles R Ashby; Yan Huang; Robert W Robey; Yong-ju Liang; Li-ming Chen; Cheng-Jun Shi; Suresh V Ambudkar; Zhe-Sheng Chen; Li-wu Fu
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

9.  Effects of Oxidized Frying Oil on Proteins Related to alpha-Tocopherol Metabolism in Rat Liver.

Authors:  Wen-Chi Huang; Zhi-Chyang Kang; Yi-Jen Li; Huey-Mei Shaw
Journal:  J Clin Biochem Nutr       Date:  2009-06-30       Impact factor: 3.114

10.  Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation.

Authors:  Stephanie E Hesselson; Pär Matsson; James E Shima; Hisayo Fukushima; Sook Wah Yee; Yuya Kobayashi; Jason M Gow; Connie Ha; Benjamin Ma; Annie Poon; Susan J Johns; Doug Stryke; Richard A Castro; Harunobu Tahara; Ji Ha Choi; Ligong Chen; Nicolas Picard; Elin Sjödin; Maarke J E Roelofs; Thomas E Ferrin; Richard Myers; Deanna L Kroetz; Pui-Yan Kwok; Kathleen M Giacomini
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.